Xenon Pharmaceuticals Inc Dossier - Source-backed chat

Xenon Pharmaceuticals Inc

XENENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.75

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $37.19Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $3.6B

Shares Outstanding 93.9M diluted

Next Earnings Date30 Jun 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Xenon Pharmaceuticals is a high-conviction neuroscience play positioned at a major inflection point. Following the positive Phase 3 X-TOLE2 trial results for its lead asset, azetukalner (XEN1101), in focal onset seizures (FOS) in March 2026, the company is on track to transition into a commercial-stage biopharma. Backed by an exceptionally strong balance sheet with $1.34 billion in cash, Xenon has a runway extending into 2029, eliminating near-term dilution risk. Azetukalner's unique mechanism as a selective Kv7 potassium channel opener offers best-in-class potential with rapid onset, no titration, and strong long-term seizure freedom rates, representing a multi-billion dollar market opportunity across epilepsy and neuropsychiatry.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets19 analysts · as of 18 Aug 2026

Low · most bearish analyst$69.00

Mean target$81.30

High · most bullish analyst$100.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$55.0010%

The FDA issues a Complete Response Letter (CRL) or requests additional clinical data for azetukalner, delaying approval and commercial launch by 12-18 months. Competitors like Biohaven or Praxis launch superior or faster-to-market Kv7 channel openers, eroding Xenon's long-term market share. MDD trials fail to meet primary endpoints, wiping out the neuropsychiatry expansion value.

Base CaseCentral scenario

$81.3060%

Matches the consensus mean

Azetukalner is approved by the FDA for FOS in late 2027 following a standard 12-month review and 3-month DEA scheduling process. Commercial launch begins in late 2027 or early 2028, capturing a significant share of the refractory epilepsy market. Peak sales in epilepsy reach $2.0 billion. MDD trials show positive but moderate efficacy, maintaining its status as a valuable call option.

Bull CaseUpside scenario

$100.0030%

Azetukalner achieves rapid FDA approval in late 2027 with a clean label, followed by a highly successful commercial launch in FOS. Peak global sales in epilepsy exceed $2.5 billion due to high physician adoption and premium pricing. Additionally, the Phase 3 X-NOVA2 trial in major depressive disorder (MDD) reads out positive in H1 2027, unlocking a massive neuropsychiatry market worth over $1 billion in incremental value.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked lead asset (azetukalner) with positive Phase 3 X-TOLE2 data in focal onset seizures demonstrating best-in-class efficacy and safety.
Robust balance sheet with $1.34 billion in cash and marketable securities as of Q1 2026, providing a runway into 2029.
Pipeline-in-a-product potential with ongoing Phase 3 trials in major depressive disorder (MDD) and bipolar depression (BPD).
Strong institutional backing (approx. 95% ownership) and strategic partnership with Neurocrine Biosciences.

Key Investment Risks

Regulatory risks associated with the upcoming NDA submission in Q3 2026 and the subsequent FDA review/DEA scheduling process.
Clinical trial risks for the ongoing Phase 3 neuropsychiatry programs (X-NOVA2, X-NOVA3, EXEDE).
Commercial execution risks as Xenon transitions from a clinical-stage R&D company to a commercial-stage entity.
Intense competition in the Kv7 potassium channel space from well-capitalized peers like Biohaven.

Thesis Invalidation Triggers

FDA refusal to file or issuance of a Complete Response Letter (CRL) for the azetukalner NDA.
Failure of the Phase 3 X-NOVA2 trial in major depressive disorder to meet its primary endpoint in H1 2027.
Significant safety signals emerging from the long-term open-label extension studies of azetukalner.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.